Close menu

July 27th, 2023 | 07:15 CEST

BioNTech, Defiance Silver, Vonovia - Waiting for the turnaround

  • Mining
  • Silver
  • Turnaround
  • Biotechnology
  • RealEstate
Photo credits:

The stock market is not a one-way street, so it happens time and again that companies that initially performed well run into problems, leading to falling prices. After an extended period of underperformance, bargain hunters often step in, seeking the right entry point to profit from a potential turnaround. One announcement can turn the tide and influence the price of a stock. We have selected three candidates where a turnaround could be imminent, provided an appropriate news catalyst exists.

time to read: 5 minutes | Author: Armin Schulz

Table of contents:

    BioNTech - Waiting for the next blockbuster

    BioNTech won the race for the Corona vaccine. That was followed by billions in revenue and record profits. The stock was soaring. Since the pandemic was officially declared over, sales and profits have been falling. For the 2nd quarter, the figures of which are to be published on August 7, analysts even expect losses. Much more important than the figures, however, is the update on the operating business. Recently, good news failed to drive the share price, such as the start of the Phase III trial of ONC-392/BNT316 in metastatic non-small cell lung cancer.

    In other biotech companies, such an announcement would be a share price driver, but in the case of the Mainz-based company, buyers have failed to materialize. Yet a cancer therapy could be the next blockbuster, and it is the first step in BioNTech's collaboration with OncoC4. Moreover, BioNTech's oncology pipeline is well-stocked, and they plan to initiate further studies with potential for approval in 2024. In addition, a building covering an area of 25,000 sqm is currently being constructed in Mainz to support further research, where cancer therapies will be the focus. It is scheduled to be operational from 2025. The success of the Comirnaty vaccine has opened the door for mRNA therapies.

    With Comirnaty's sales not expected to grow, even though it has submitted joint applications with Pfizer to the US FDA for the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, the focus is on the product pipeline. In Germany, the stock has been running sideways between EUR 91.62 and EUR 110.20 since mid-May. The share is currently trading at EUR 96.88. On the NASDAQ, the psychologically important mark of USD 100 has been held so far. If the mark breaks, the share could drop further.

    Defiance Silver - Awaiting the conclusion of the legal proceedings

    Defiance Silver is active in Mexico, where it owns the Zacateca Silver Project, consisting of four properties named San Acacio, Lucita, Lagartos, and Panuco, as well as the Tepal Gold-Copper Project. On June 7, initial results from the San Acacio drill program were released. The 4 holes evaluated had the highest grades and widest widths of mineralization on the property to date. Of particular note is hole DDSA-23-66, which returned the widest width to date: 41.83 m at 157.30 g/t silver. Peak silver grade was 5,510 g/t or 6,014 g/t silver equivalent. The original initial resource estimate was for 16.9 million ounces of silver, and since then, additional significant discoveries have been made outside the original drill area. The Veta Grande vein system, in particular, appears to have very high-grade mineralization.

    The other 3 Zacateca properties are still at an early exploration stage, but again, initial drilling has already found very high grades of silver. The facts and figures speak for themselves, yet the share has been under pressure since May 2021. The reason for this is the Tepal project, which according to a NI 43-101 resource estimate, hosts over 1.8 million ounces of gold and 813 million pounds of copper and has a completed pre-feasibility study. Work has been unable to continue here for some time because fraudsters have managed to transfer the mineral concessions to a third party using forged documents. A legal dispute has been ongoing ever since. Douglas Cavey, the Executive Vice President, stated at the gold conference in Frankfurt that the Company has the support of the Minister of Economy and also enjoys backing from the Mexican mining industry.

    He hopes that the process will be concluded positively in the next 10 months and that the project can then be moved forward. If the corresponding announcement comes, the share price should turn around abruptly. **In 2021, the share price was still over CAD 1. Currently, one share certificate can be bought for CAD 0.16, giving the Company a market capitalization of just CAD 36.4 million. Approximately CAD 5.5 million in cash is available for the exploration work this year and for the final payments to bring Lucita and San Acacio into 100% ownership. Risk-averse investors can build an initial position here.

    Vonovia - Waiting for the end of interest rate hikes

    Vonovia is considered the largest real estate group in Europe. The ECB's zero interest rate policy played into the Company's cards. It grew without paying interest and made acquisitions such as Deutsche Wohnen. As a result, the debts have increased, and since the outbreak of the Ukraine conflict, inflation has been on the rise. The US Federal Reserve (FED) has tried since then to stop the price increase by raising the interest rates. On July 26, the FED will likely raise interest rates by another 0.25%. This, in turn, puts pressure on the ECB because inflation is still stronger in Europe than in the US.

    Any upward move in interest rates is poison for the indebted Vonovia Group. Interest expenses for the debt, which could previously be refinanced cheaply for a long time, are now rising significantly. As a result, earnings are falling. The Group has already sold properties for several billion euros and halved dividends to give itself breathing room. In addition, real estate prices are falling, as many people can no longer afford to buy property due to increased interest rates. Vonovia's tenants are also suffering from inflation, and there are fears that some tenants could default on their payments.

    There has recently been a tailwind from Deutsche Bank, which believes that the fall in real estate prices has been halted for now. On the one hand, this means there are fewer balance sheet problems. On the other hand, this creates a more favorable environment for buyers, who may now be more inclined to purchase at current levels. EUR 300 million is retained by the Company, as around 45% of shareholders have opted for a stock dividend. The share has bounced off the all-time low of EUR 15.21 and can be had for EUR 20.93. The average price target of analysts is EUR 28.99. As soon as the central banks announce the end of interest rate hikes, this would be an initial spark for real estate stocks.

    For all three companies, the outlook is good. In the case of BioNTech, only one preparation against cancer would have to be approved, and buyers would be lining up. Defiance Silver only needs official confirmation from the court that the fraud case will be reversed and can then hit the ground running. Vonovia is dependent on the central banks. The high level of debt is squeezing and must remain refinanceable. However, interest rates are still rising, which is likely to create further pressure.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 28th, 2023 | 09:05 CEST

    Germany - Car Country? The exodus begins: Mercedes-Benz, Volkswagen, First Phosphate

    • Mining
    • phosphate
    • Electromobility
    • Energy

    Cars still play a significant role in Germany. Many households have two vehicles, some even more. However, sales of new cars have weakened recently - the question of whether to buy a combustion engine or an electric vehicle, along with inflation, have deterred many buyers. German brand manufacturers are now being attracted to the US. There, they are enticed by subsidies and an intact market. Find out what the latest plans of Mercedes-Benz, Volkswagen, and others entail and which relatively unknown company could benefit.


    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.